Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 616-623

  Tokuhira, Michihide ^a   Watanabe, Reiko ^a   Nemoto, Tomoe ^a   Sagawa, Morihiko ^a   Tomikawa, Tatsuki ^a   Tamaru, Jun Ichi ^a   Itoyama, Shinji ^a   Nagasawa, Hayato ^a   Amano, Koichi ^a   Kameda, Hideto ^b   Takeuchi, Tsutomu ^b   Mori, Shigehisa ^a   Kizaki, Masahiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Iatrogenic; Lymphoproliferative disorder; Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; BLEOMYCIN; BUCILLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IATROGENIC DISEASE; IMMUNE DEFICIENCY; KARYOTYPE; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDICAL RECORD; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOLOGY; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, CD30; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMOSOME ABERRATIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84859069205     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.625101     Document Type: Article

References (25)

1. S, Harris NL, Jaff e ES, et al. Other iatrogenic immunodefi ciency-associated lymphoproliferative disorders. In: Swerdlow SH CE, Harris NL, Jaff e ES, Pileri SA, Stein H, Th iele J, Vardiman JW, editors. WHO Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues Vol., 4th edn. IARC: Lyon; 2008. pp. 350 - 351.
2. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. New England Journal of Medicine 1993;328:1317-1321.
3. Hoshida Y, Tomita Y, Zhiming D, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. International Journal of Cancer 2004;108:443-449.
4. Kamel OW, van de Rijn M, Hanasono MM, et al. Immunosuppressionassociated lymphoproliferative disorders in rheumatic patients. Leukemia & Lymphoma 1995;16:363-368.
5. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. Journal of Rheumatology 2007;34:322-331.
6. Weinblatt ME, Coblyn JS, Fox DA, et al. Effi cacy of low-dose methotrexate in rheumatoid arthritis. New England Journal of Medicine 1985;312:818-822.
7. Swierkot J, Szechi ński J. Methotrexate in rheumatoid arthritis. Pharmacological Report 2006;58:473-492.
8. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. Journal of American Academy of Dermatology 2004;51:660-662.
9. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis & Rheumatism 2010; 62:2517-2524.
10. Rizzi R, Curci P, Delia M, et al. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Medical Oncology 2009;26:1-9.
11. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. American Journal of Hematology 2007;82:1106-1109.
12. Baird RD, van Zyl-Smit RN, Dilke T, et al. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. British Journal of Haematology 2002;118:567-568.
13. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Clinical Oncology 1996;14:1943-1949.
14. Parada LA, Hallé n M, Tranberg KG, et al. Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer. Genes, Chromosomes and Cancer 1998;23:26-35.
15. Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998;91:1732-1741.
16. Hasserjian RP, Chen S, Perkins SL, et al Immunomodulator agent-related lymphoproliferative disorders. Modern Pathology 2009;22:1532-1540.
17. Alspaugh MA, Henle G, Lennette ET, et al. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fl uids of patients with rheumatoid arthritis. Journal of Clinical Investigation 1981;67:1134-1140.
18. Sawada S, Takei M. Epstein-Barr virus etiology in rheumatoid synovitis. Autoimmunity Reviews 2003;4:106-110.
19. Balandraud N, Meynard JB, Auger I, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantifi cation using real-time polymerase chain reaction. Arthritis & Rheumatism 2003;48:1223-1228.
20. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-3915.
21. Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Science 2010; 101:1309-1313.
22. Moder KG, Teff eri A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. American Journal of Medicine 1995;99:276-281.
23. Baecklund E, Backlin C, Iliadou A, et al. Characteristics of diff use large B cell lymphomas in rheumatoid arthritis. Arthritis & Rheumatism 2006;54:3774-3781.
24. Balandraud N, Meynard JB, Auger I, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantifi cation using real-time polymerase chain reaction. Arthritis & Rheumatism 2003;48:1223-1228.
25. Lioté F, Pertuiset E, Cochand-Priollet B, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. Journal of Rheumatology 1995;22:1174-1178.